LIXTE Biotechnology is advancing its cancer therapy pipeline with LB-100, a protein phosphatase 2A inhibitor targeting ovarian clear cell carcinoma, soft tissue sarcoma, and metastatic colon cancer, with potential trial results expected in late 2025.

LIXTE Biotechnology Holdings, Inc. has filed a request to withdraw its Registration Statement on Form S-1, as the company no longer intends to pursue a public offering at this time.

Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system

Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system

LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing